US Patent

US9700530 — Capsule dosage form of metoprolol succinate

Formulation · Assigned to Sun Pharmaceutical Industries Ltd · Expires 2035-07-09 · 9y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an extended-release capsule dosage form of metoprolol succinate that can be sprinkled onto food for easier administration.

USPTO Abstract

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed Toprol-XL® tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.

Drugs covered by this patent

Patent Metadata

Patent number
US9700530
Jurisdiction
US
Classification
Formulation
Expires
2035-07-09
Drug substance claim
No
Drug product claim
Yes
Assignee
Sun Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.